Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort | Zendy

Giulio Metro | Zendy; Alfredo Addeo | Zendy; Diego Signorelli | Zendy; Alessio Gili | Zendy; Panagiota Economopoulou | Zendy; Fausto Roila | Zendy; Giuseppe Luigi Banna | Zendy; Alessandro De Toma | Zendy; Juliana Rey Cobo | Zendy; Andrea Camerini | Zendy; Athina Christopoulou | Zendy; Giuseppe Lo Russo | Zendy; Marco Banini | Zendy; Domenico Galetta | Zendy; Beatriz Jiménez | Zendy; Ana Collazo-Lorduy | Zendy; Antonio Calles | Zendy; Panagiotis Baxevanos | Zendy; Helena Linardou | Zendy; P. Kosmidis | Zendy; Marina Chiara Garassino | Zendy; Giannis Mountzios | Zendy

Open Access

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

Author(s) -

Giulio Metro,

Alfredo Addeo,

Diego Signorelli,

Alessio Gili,

Panagiota Economopoulou,

Fausto Roila,

Giuseppe Luigi Banna,

Alessandro De Toma,

Juliana Rey Cobo,

Andrea Camerini,

Athina Christopoulou,

Giuseppe Lo Russo,

Marco Banini,

Domenico Galetta,

Beatriz Jiménez,

Ana Collazo-Lorduy,

Antonio Calles,

Panagiotis Baxevanos,

Helena Linardou,

P. Kosmidis,

Marina Chiara Garassino,

Giannis Mountzios

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.12.23

Subject(s) - pembrolizumab , medicine , salvage therapy , chemotherapy , oncology , lung cancer , regimen , progressive disease , chemotherapy regimen , surgery , immunotherapy , cancer

In this real-world multicenter study we addressed the activity of post-progression anticancer treatments after first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥50%.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research